Find Funding Opportunities

The purpose of this Notice is to inform the community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Funding Opportunity Announcement (FOA) that will solicit applications for the Stroke Preclinical Assessment Network (SPAN)- Interventions from Small Businesses. SPAN supports late-stage preclinical efficacy studies of putative cerebroprotectants to be given prior to or at the time of reperfusion in experimental stroke models. Parallel testing of the most promising interventions in a network structure will help to determine if an intervention can improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, with the overall end goal of guiding the selection of the most promising agent(s) to transition to future Phase II clinical trials (to be conducted through StrokeNet). SPAN will consist of one Coordinating Center (CC), several testing laboratories, and intervention contributors. This infrastructure is expected to test multiple interventions in animal models of transient cerebral ischemia.

The purpose of this notice is to clarify the Award Budget for RFA-NS-22-009.

NIDA, with other NIH Blueprint for Neuroscience Research Institutes and Centers (ICs), intends to reissue initiative RFA-DA-16-009. The program is designed to either establish new research training programs or to support the continuation of meritorious existing training programs in computational neuroscience and behavior and for undergraduate and predoctoral level students. This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. The overall objectives of the program have not changed, however, minor changes to improve the clarity and focus of the previous announcement are expected. The FOA is expected to be published in early 2022 with an expected application due date in Fall 2022.

The purpose of this time-sensitive Request for Information (RFI) is to seek input from scientists, clinicians, patients, families, caregivers, advocates, and the broader dementia community on the most important needs and promising opportunities for Alzheimer's disease-related dementias (ADRD) research. The information submitted in response to this RFI will be used by committees of scientists, clinicians, and other members of the public to revise and update the ADRD 2019 research recommendations.

This notice informs potential applicants that XYZ is participating, effective immediately in RFA-NS-22-016 "HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)".

The purpose of this Notice is to alert potential applicants to the early expiration of PAR-20-316 "NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)". This FOA will expire on October 1, 2021.

The purpose of this Notice is to announce the posting of the frequently asked questions regarding RFA-HD-22-007 for Autism Centers of Excellence (R01) and RFA-HD-22-008 for Autism Centers of Excellence (P50). They are available for viewing at: www.nichd.nih.gov/sites/default/files/inline-files/ACE_FAQs_09132021.pdf.

The purpose of this notice is to update the Funding Opportunity Announcement (FOA) used to solicit applications through NOT-NS-20-038 "Notice of Special Interest (NOSI): Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)". The Parent Administrative Supplement PA-18-591 "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)" has expired. It has been reissued as PA-20-272 "https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html". Applicants should use PA-20-272 to solicit applications through this NOSI.

This Notice modifies key dates of RFA-MH-21-175.

The purpose of this notice is to extend the due date for PAR-22-029 "Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)".